Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in New York: - Women's Cancer Care Associates LLC — Albany, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07198074
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Stony Brook University Medical Center — Stony Brook, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in New York: - Women's Cancer Care Associates, LLC — Albany, New York
- NYU Langone Hospital-Long Island — Mineola, New York
- Northwell Health - Zuckerberg Cancer Center — New Hyde Park, New York
- Mount Sinai Chelsea — New York, New York
- Perlmutter Cancer Center at NYU Langone Health — New York, New York
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in New York: - Research Site — Brooklyn, New York
- Research Site — Stony Brook, New York
- Research Site — The Bronx, New York
- Research Site — White Plains, New York
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in New York: - Research Site — New York, New York
- Research Site — New York, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicate…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06952504
Sites in New York: - Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004) — New York, New York
Phase 2, Phase 3 Recruiting Industry
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part…
Sponsor: Kartos Therapeutics, Inc.
NCT ID: NCT05797831
Sites in New York: - Good Samaritan Hospital Medical Center — West Islip, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachyther…
Sponsor: Kara Romano, MD
NCT ID: NCT03785288
Sites in New York: - SUNY Upstate Medical University — Syracuse, New York
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- State University of New York Upstate Medical University — Syracuse, New York
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- University of Rochester — Rochester, New York
- State University of New York Upstate Medical University — Syracuse, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 2 Recruiting Industry
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
NCT ID: NCT05548296
Sites in New York: - Laura & Isaac Perlmutter Cancer Center — New York, New York
- New York Presbyterian Hospital-Columbia University Medical Center — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Mount Sinai Health System — New York, New York
- University of Rochester Medical Center — Rochester, New York
Phase 2 Recruiting Network
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05640999
Sites in New York: - Mount Sinai Chelsea — New York, New York
- Mount Sinai Hospital — New York, New York
- Upstate Cancer Center Radiation Oncology at Oswego — Oswego, New York
- State University of New York — Syracuse, New York
- Upstate Cancer Center at Hill Radiation Oncology — Syracuse, New York
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in New York: - Hematology Oncology Associates of Central New York — East Syracuse, New York
- Northwell Health Cancer Institute — Lake Success, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in New York: - Northwell Health — Lake Success, New York
- Laura & Isaac Perlmutter Cancer Center at NYC Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists — Shirley, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University — New York, New York
- Memorial Sloan Kettering — New York, New York
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…
Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in New York: - NYU Langone Health- Long Island — Mineola, New York
- NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in New York: - Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer.…
Sponsor: Alliance Foundation Trials, LLC.
NCT ID: NCT04486352
Sites in New York: - Roswell Park — Buffalo, New York
- Weill Cornell Medicine — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in New York: - Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in New York: - Women's Cancer Care Associates, LLC — Albany, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in New York: - Memorial Sloan-Kettering Cancer Center — New York, New York